Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 8/20 | 0.46 |
| ▸ | MET | P08581 | 5/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | TEK | Q02763 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 5/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24028711 | 0.89 | KDR (0.49) | KDRMETAURKATEKAURKB | |
| SCHEMBL24028714 | 0.85 | MET (0.51) | KDRMETAURKATEKAURKB | |
| SCHEMBL24028883 | 0.84 | KDR (0.46) | CA12CA1CA2CA9KDR | |
| SCHEMBL24028336 | 0.83 | KDR (0.49) | KDRMETAURKATEKAURKB | |
| SCHEMBL24028337 | 0.82 | KDR (0.48) | KDRMETAURKATEKAURKB | |
| SCHEMBL24028324 | 0.82 | MET (0.48) | KDRMETAURKATEKAURKB | |
| SCHEMBL25223465 | 0.81 | KDR (0.50) | KDRMETAURKATEKAURKB | |
| SCHEMBL24028332 | 0.80 | KDR (0.51) | KDRMETAURKATEKAURKB | |
| SCHEMBL24028325 | 0.80 | MET (0.48) | KDRMETAURKATEKAURKB | |
| SCHEMBL24028322 | 0.80 | KDR (0.49) | KDRMETAURKATEKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2021231726-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | CA12 4883/4885CA1 4872/4885CA2 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.